Monthly Archives: March 2015

Biothera to Participate in Novel Immunomodulatory Therapies Panel Discussion at Cancer Progress Conference

EAGAN, MN — March 16, 2015 — Ada Braun, M.D., Ph.D., Chief Medical Officer for Biothera’s Pharmaceutical business, will participate in an expert panel discussion of novel immunomodulatory therapies tomorrow at the 26th Annual Cancer Progress Conference in New York, NY. The panel will include leading clinicians and researchers from major pharmaceutical companies focused on new therapies that engage the immune system to fight cancer....

Read More


Biothera’s Investigational Cancer Immunotherapy Imprime PGG Neutralizes Cancer Defense Mechanisms in the Tumor Microenvironment

New Preclinical Data to be presented today at Keystone Symposium in Montreal EAGAN, MN, March 9, 2015 — New preclinical research from Biothera further demonstrates the ability of its cancer immunotherapy drug candidate Imprime PGG® to initiate a cascade effect of immune responses that neutralize cancer-associated immunosuppression in the tumor microenvironment. Biothera will present the new data today in Montreal at the Keystone Symposium: Dendritic...

Read More